Relapsed/Refractory Multiple Myeloma — Proceedings from a Session Held in Conjunction with the 2026 ASCO Annual Meeting

Featuring perspectives from Dr Melissa Alsina, Dr Hans Lee, Dr Sagar Lonial and Dr Paul G Richardson, moderated by Dr Lonial, including the following topics:
• Introduction (0:00)
• Integrating Bispecific Antibodies into the Management of Relapsed/Refractory (R/R) Multiple Myeloma (MM) — Dr Lee (1:45)
• Current Utility of Antibody-Drug Conjugates for MM — Dr Lonial (33:55)
• Potential Role of Cereblon E3 Ligase Modulators in Therapy for MM — Dr Richardson (59:42)
• Chimeric Antigen Receptor T-Cell Therapy for R/R MM — Dr Alsina (1:30:24)

CME information and select publications (researchtopractice.com/ASCO2026/RRMM/Video)